Bioatla Rg

Clinical‑stage biotech BioAtla develops selective antibody‑drug conjugates targeting solid tumors, including sarcoma and NSCLC. Its portfolio features BA3011, BA3021, and BA3071, positioning it for high‑impact oncology therapies.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 61
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
BCAB	Bioatla Rg Cap: 0.0B	EQUITY	NMS	USD	US09077B1044	Active	📈